Scientific Resources
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Application